ClinicalTrials.gg
CompletedNCT04676412LEAP-007Updated Apr 4, 2025Results posted

Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) [MK-7902-007/E7080-G000-314/LEAP-007] - China Extension Study

A Phase 3 interventional study of Pembrolizumab and Lenvatinib in Non-small Cell Lung Cancer, sponsored by Merck Sharp & Dohme LLC. Completed at 17 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-04.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 1 month after the study started (first participant enrolled Oct 2019, registered Dec 2020).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
107
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing lenvatinib in Carcinoma, Non-Small-Cell Lung — 3 open to participants now, 4 under way, 1 of them phase 3. lenvatinib · Carcinoma, Non-Small-Cell Lung.

Enrollment
4th of 14
107 · median 29
Started
2019
with 2 others
Phase 3
4 of 14
1 open now
Registered
7th of 14
by date
Lead sponsor
3 of 14
Merck Sharp & Dohme LLC

Among the 14 studies testing lenvatinib in Carcinoma, Non-Small-Cell Lung, this one is the 4th largest by enrollment, is one of 3 that started in 2019, is one of 4 in phase 3, and was the 7th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

3 of the 14 studies testing lenvatinib in Carcinoma, Non-Small-Cell Lung are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About lenvatinib

lenvatinib: first FDA approval 2015 (LENVIMA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing lenvatinib in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety and efficacy of pembrolizumab (MK-3475) combined with lenvatinib (MK-7902/E7080) compared to pembrolizumab alone (with placebo for lenvatinib) in treatment-naïve adults with no prior systemic therapy for their metastatic non-small cell lung cancer (NSCLC) whose tumors have a programmed cell death-ligand 1 (PD-L1) Tumor Proportion Score (TPS) greater than or equal to 1%.

The primary study hypotheses are that: 1) the combination of pembrolizumab and lenvatinib is superior to pembrolizumab alone as assessed by Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1); and 2) the combination of pembrolizumab and lenvatinib is superior to pembrolizumab alone as assessed by Overall Survival (OS).

Read the detailed description

The main study will have a duration of approximately 5 years and the extension period will have a duration of approximately 1 year. The base study and the China extension to MK-7902-007 (NCT03829332) will enroll a total of approximately 120 Chinese participants.

As of 30-Jul-2021, active participants, investigator, and sponsor personnel or delegate(s) involved in the treatment administration or clinical evaluation of the participants will be unblinded. Participants will discontinue lenvatinib and placebo, and participants who remain on treatment will receive open-label pembrolizumab only.

03

Conditions studied

  • Non-small Cell Lung Cancer

Keywords

  • programmed cell death 1 (PD-1, PD1)
  • programmed cell death-ligand 1 (PD-L1, PDL1)
  • programmed cell death-ligand 2 (PD-L2, PDL2)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has a or cytologically confirmed diagnosis of non-small cell lung cancer (NSCLC)
  • Has Stage IV NSCLC (American Joint Committee on Cancer [AJCC])
  • Has based on 1.1 (RECIST 1.1)
  • Has tumor tissue that demonstrates programmed cell death-ligand 1 () expression in ≥1% of tumor cells (Tumor Proportion Score [TPS] ≥1%) as assessed by immunohistochemistry (IHC) 22C3 pharmDx assay (Dako North America, Inc.) at a central laboratory
  • Has a of ≥3 months
  • Has an (ECOG) performance status of 0 or 1 within 7 days before the first dose of study treatment but before randomization
  • Male participants must agree to the following during the treatment period and for ≥7 days after the last dose of lenvatinib/matching placebo: 1) Be abstinent from heterosexual intercourse as their preferred and usual lifestyle and agree to remain abstinent, OR 2) Must agree to use unless confirmed to be azoospermic (vasectomized or secondary to medical cause)
  • Female participants are eligible to participate if not pregnant or breastfeeding, and ≥1 of the following applies: 1) Is not a woman of (WOCBP), OR 2) Is a WOCBP and is using a highly effective contraceptive method that has a low user dependency, or be abstinent from heterosexual intercourse as their preferred and usual lifestyle during the treatment period and for ≥120 days post pembrolizumab or ≥30 days post lenvatinib/matching placebo, whichever occurs last
  • Has adequately controlled blood pressure (BP) with or without antihypertensive medications, defined as BP ≤150/90 mm Hg and no change in antihypertensive medications within 1 week before randomization
  • Has adequate organ function

Exclusion criteria

Exclusion Criteria:

  • Has known untreated central nervous system and/or carcinomatous meningitis
  • Has a known history of an additional , except if the participant has undergone potentially curative therapy with no evidence of that disease recurrence for ≥3 years since initiation of that therapy (Note: The time requirement does not apply to participants who underwent successful definitive resection of basal cell carcinoma of the skin, superficial bladder cancer, squamous cell carcinoma of the skin, in situ cervical cancer, or other in situ cancers.)
  • Has radiographic evidence of encasement or invasion of a major blood vessel, or of intratumoral cavitation
  • Has an active disease that has required systemic treatment in the past 2 years Replacement therapy (e.g. thyroxine, insulin, or physiologic replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment and is allowed
  • Has had an allogeneic tissue/solid organ transplant
  • Has a known history of (HIV) infection
  • Has a history of (noninfectious) pneumonitis that required systemic steroids or current pneumonitis/interstitial lung disease
  • Has a known history of or known active virus infection
  • Has a history of a gastrointestinal condition or procedure that in the opinion of the investigator may affect oral study drug absorption
  • Has significant cardiovascular impairment within 12 months of the first dose of study treatment, such as a history of congestive heart failure greater than Class II, unstable angina, myocardial infarction, cerebrovascular accident/stroke, or cardiac arrhythmia associated with hemodynamic instability
  • Has not recovered adequately from any toxicity and/or complications from major surgery before starting study treatment
  • Has a known history of active tuberculosis (TB)
  • Has an active infection requiring systemic therapy
  • Has previously had a severe reaction to treatment with a monoclonal antibody or has a known sensitivity or intolerance to any component of lenvatinib or pembrolizumab
  • Has received prior systemic chemotherapy or other targeted or biological antineoplastic therapy for their metastatic NSCLC
  • Has received prior therapy with an , anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g. cytotoxic T-lymphocyte-associated protein 4 [CTLA-4], Tumor necrosis factor receptor superfamily, member 4 [OX 40], tumor necrosis factor receptor superfamily member 9 [CD137]) or has received lenvatinib as monotherapy or in combination with anti- programmed cell death protein (anti-PD-1) agents
  • Has received radiotherapy within 14 days before the first dose of study treatment or received lung radiation therapy of >30 Gray (Gy) within 6 months before the first dose of study treatment. (Note: Participants must have recovered from all radiation-related toxicities to ≤Grade 1, not require corticosteroids, and not have had radiation pneumonitis.)
  • Has a diagnosis of immunodeficiency or is receiving any form of therapy within 7 days before the first dose of study treatment
  • Is receiving systemic steroid therapy (doses >10 mg daily of prednisone equivalent) within 7 days before the first dose of study treatment
  • Has received a within 30 days before the first dose of study treatment
  • Has had major surgery within 3 weeks prior to first dose of study treatment
  • Has pre-existing ≥Grade 3 gastrointestinal or non-gastrointestinal fistula
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
107 participants (actual)

Study arms

  • Experimental
    Pembrolizumab + Lenvatinib

    Participants receive pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years) PLUS lenvatinib 20 mg via oral capsule once daily (QD) on Days 1-21 of each 3-week cycle until progressive disease or unacceptable toxicity.

    Biological: Pembrolizumab · Drug: Lenvatinib

  • Active comparator
    Pembrolizumab + Placebo

    Participants receive pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years) PLUS placebo for lenvatinib via oral capsule QD on Days 1-21 of each 3-week cycle until progressive disease or unacceptable toxicity.

    Biological: Pembrolizumab · Drug: Placebo for lenvatinib

Interventions

  • BiologicalPembrolizumab

    IV infusion

    Also known as: MK-3475, KEYTRUDA®

  • oral capsule

    Also known as: MK-7902, E7080, LENVIMA®

  • DrugPlacebo for lenvatinib

    oral capsule

06

What researchers measure

Primary outcomes

  1. Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)

    PFS was defined as the time from date of randomization to the date of the first documentation of progressive disease (PD) or death from any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. Note: The appearance of one or more new lesions was also considered PD. Data were from the product-limit (Kaplan-Meier) method for censored data. PFS as assessed by BICR per RECIST 1.1 was presented.

    Time frame: Up to approximately 18 months

  2. Overall Survival (OS)

    OS was defined as the time from date of randomization to date of death from any cause.

    Time frame: Up to approximately 18 months

Secondary outcomes

  1. Objective Response Rate (ORR) Per RECIST 1.1 as Assessed by BICR

    ORR was defined as the percentage of participants with Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. The percentage of participants who experienced CR or PR as assessed by BICR were presented.

    Time frame: Up to approximately 18 months

  2. Number of Participants Who Experienced an Adverse Event (AE)

    An AE was any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experienced an AE were reported.

    Time frame: Up to approximately 52 months

  3. Number of Participants Who Discontinued Study Treatment Due to an AE

    An AE was any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who discontinued study treatment due to an AE were reported

    Time frame: Up to approximately 30 months

  4. Change From Baseline in European Organization for Research and Treatment (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Combined Global Health Status / Quality of Life (Items 29 & 30) Scale Combined Score

    EORTC QLQ-C30 is a questionnaire to assess the overall quality of life (QoL) of cancer patients. Participant responses to questions regarding Global Health Status (GHS; "How would you rate your overall health during the past week?") and QoL ("How would you rate your overall quality of life during the past week?") are scored on a 7-point scale (1= Very poor to 7=Excellent). The combined score of GHS (Item 29) and QoL (Item 30) is computed by averaging the raw scores of the 2 items and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome. Per protocol, the change from baseline in GHS and QoL combined score was presented.

    Time frame: Baseline and Week 21

  5. Change From Baseline in Cough (EORTC Quality of Life Questionnaire-Lung Cancer Module 13 [QLQ-LC13] Item 31) Score

    The EORTC QLQ-LC13 is a lung cancer-specific supplemental questionnaire used in combination with the EORTC QLQ-C30. Participant responses to the question "How much did you cough?" are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. The change from baseline in cough (EORTC QLQ-LC13 Item 31) score will be presented. A lower score indicates a better outcome.

    Time frame: Baseline and Week 21

  6. Change From Baseline in Chest Pain (EORTC QLQ-LC13 Item 40) Score

    The EORTC QLQ-LC13 is a lung cancer-specific supplemental questionnaire used in combination with the EORTC QLQ-C30. Participant responses to the question "Have you had pain in your chest?" are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. The change from baseline in chest pain (EORTC QLQ-LC13 Item 40) score was reported. A lower score indicated a better outcome.

    Time frame: Baseline and Week 21

  7. Change From Baseline in Dyspnea (EORTC QLQ-C30 Item 8) Score

    The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant responses to the question "Were you short of breath?" are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. The change from baseline in dyspnea (EORTC QLQ-C30 Item 8) score was reported. A lower score indicated a better outcome.

    Time frame: Baseline and Week 21

  8. Change From Baseline in Physical Functioning (EORTC QLQ-C30 Items 1-5) Score

    EORTC QLQ-C30 is a questionnaire to assess the overall QoL of cancer patients. Participant responses to 5 questions about their physical functioning (Items 1 to 5) are scored on a 4-point scale (1=Not at All to 4=Very Much). The combined score of items 1 to 5 was computed by averaging the raw scores of the 5 items and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome. Per protocol, the change from baseline in EORTC QLQ-C30 physical functioning (Items 1-5) combined score was presented.

    Time frame: Baseline and Week 21

  9. Time to True Deterioration (TTD) in EORTC QLQ-C30 Combined Global Health Status /Quality of Life (Items 29 & 30) Scale Combined Score

    EORTC QLQ-C30 is a questionnaire to assess QoL of cancer patients. Participant responses to questions on GHS ("How would you rate your overall health during the past week?") and QoL ("How would you rate your overall QoL during the past week?") were scored on a 7-point scale (1= Very poor to 7=Excellent). The combined score of GHS (Item 29) and QoL (Item 30) was computed by averaging raw scores of the 2 items and applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome. TTD was defined as the time from baseline to first onset of ≥10-point negative change (decrease) from baseline in GHS-QoL combined score. A longer TTD indicates a better outcome.

    Time frame: Up to approximately 25 months

  10. Time to True Deterioration (TTD) in EORTC QLQ-LC13 Cough (Item 31) Scale Score

    EORTC QLQ-LC13 is a lung cancer specific questionnaire. Participant responses to the question: "How much did you cough?" are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0-100. A lower score indicates a better outcome. TTD was defined as the time from baseline to first onset of ≥10-point negative change (decrease) from baseline in cough (Item 31). A longer TTD indicates a better outcome.

    Time frame: Up to approximately 25 months

  11. Time to True Deterioration (TTD) in EORTC QLQ-LC13 Chest Pain (Item 40) Scale Score

    EORTC QLQ-LC13 is a lung cancer specific questionnaire. Participant responses to the question: "Have you had pain in your chest?" are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0-100. A lower score indicates a better outcome. TTD was defined as the time from baseline to first onset of ≥10-point negative change (decrease) from baseline in cough (Item 40). A longer TTD indicates a better outcome.

    Time frame: Up to approximately 25 months

  12. Time to True Deterioration (TTD) in EORTC QLQ-C30 Dyspnea (Item 8) Scale Score

    EORTC QLQ-C30 is a questionnaire to assess the overall QoL of cancer patients. Participant responses to the question: "Were you short of breath?" are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A lower score indicates a better outcome. TTD was defined as the time from baseline to first onset of ≥10-point negative change (decrease) from baseline in dyspnea (Item 8). A longer TTD indicates a better outcome.

    Time frame: Up to approximately 25 months

  13. Time to True Deterioration (TTD) in the Composite Endpoint of EORTC QLQ-LC13 Cough (Item 31), EORTC QLQ-LC13 Chest Pain (Item 40), or EORTC QLQ-C30 Dyspnea (Item 8)

    The EORTC QLQ-C30 is a 30-item questionnaire developed to assess the QoL of cancer patients, including a single-item scale score for dyspnea (Item 8; score range:1=Not at All to 4=Very Much). Used in combination with QLQ-C30, the EORTC QLQ-LC13 is a supplemental lung cancer-specific module, including a single-item scale score for cough (Item 31; score range:1=Not at All to 4=Very Much ) and chest pain (Item 40, score range: 1=Not at All to 4=Very Much). The combined score of items 31, 40 and 8 was computed by averaging the raw scores of the items and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome. The TTD in the composite endpoint of EORTC QLQ-LC13 Item 31, EORTC QLQ-LC13 Item 40, EORTC QLQ-C30 Item 8 scale score was presented, defined as the time to first onset of a ≥10point decrease from baseline in anyone of the three scale items. A longer TTD indicates better outcome.

    Time frame: Up to approximately 25 months

  14. Time to True Deterioration (TTD) Based on Change From Baseline in EORTC QLQ-C30 Physical Functioning (Items 1-5) Score

    EORTC QLQ-C30 is a questionnaire to assess the overall QoL of cancer patients. Participant responses to 5 questions about their physical functioning (Items 1 to 5) are scored on a 4-point scale (1=Not at All to 4=Very Much). The combined score of items 1 to 5 was computed by averaging the raw scores of the 5 items and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome. TTD was defined as the time from baseline to first onset of ≥10-point negative change (decrease) from baseline in physical functioning (Items 1 to 5). A longer TTD indicates a better outcome.

    Time frame: Up to approximately 25 months

07

Results

Posted Nov 9, 2022

Participant flow

Participant flow — Overall Study
MilestonePembrolizumab + LenvatinibPembrolizumab + Placebo
Started4958
Completed00
Not completed4958
Withdrew: Death2831
Withdrew: Lost to follow-up12
Withdrew: Sponsor decision2023
Withdrew: Withdrawal by subject02

Outcome measures

SecondaryObjective Response Rate (ORR) Per RECIST 1.1 as Assessed by BICR

ORR was defined as the percentage of participants with Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. The percentage of participants who experienced CR or PR as assessed by BICR were presented.

Time frame:
Up to approximately 18 months
Reported as:
Number · Percentage of participants
Objective Response Rate (ORR) Per RECIST 1.1 as Assessed by BICR
Percentage of participantsPembrolizumab + LenvatinibPembrolizumab + Placebo
Objective Response Rate (ORR) Per RECIST 1.1 as Assessed by BICR33.3 (19.6 to 49.5)39.6 (26.5 to 54.0)
Statistical analysis
  • Pembrolizumab + Lenvatinib vs Pembrolizumab + Placebo · Stratified Miettinen and Nurminen · p = 0.79262 · Difference in percentage: -8.4 · 95% CI -27.4 to 11.9One-sided p-value for testing. H0: difference in percentage =0 versus H1: difference in percentage \> 0
SecondaryNumber of Participants Who Experienced an Adverse Event (AE)

An AE was any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experienced an AE were reported.

Time frame:
Up to approximately 52 months
Reported as:
Count of participants · Participants
Number of Participants Who Experienced an Adverse Event (AE)
ParticipantsPembrolizumab + LenvatinibPembrolizumab + Placebo
Number of Participants Who Experienced an Adverse Event (AE)4957
SecondaryNumber of Participants Who Discontinued Study Treatment Due to an AE

An AE was any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who discontinued study treatment due to an AE were reported

Time frame:
Up to approximately 30 months
Reported as:
Count of participants · Participants
Number of Participants Who Discontinued Study Treatment Due to an AE
ParticipantsPembrolizumab + LenvatinibPembrolizumab + Placebo
Number of Participants Who Discontinued Study Treatment Due to an AE1913
SecondaryChange From Baseline in European Organization for Research and Treatment (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Combined Global Health Status / Quality of Life (Items 29 & 30) Scale Combined Score

EORTC QLQ-C30 is a questionnaire to assess the overall quality of life (QoL) of cancer patients. Participant responses to questions regarding Global Health Status (GHS; "How would you rate your overall health during the past week?") and QoL ("How would you rate your overall quality of life during the past week?") are scored on a 7-point scale (1= Very poor to 7=Excellent). The combined score of GHS (Item 29) and QoL (Item 30) is computed by averaging the raw scores of the 2 items and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome. Per protocol, the change from baseline in GHS and QoL combined score was presented.

Time frame:
Baseline and Week 21
Reported as:
Least squares mean · Score on a scale
Change From Baseline in European Organization for Research and Treatment (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Combined Global Health Status / Quality of Life (Items 29 & 30) Scale Combined Score
Score on a scalePembrolizumab + LenvatinibPembrolizumab + Placebo
Change From Baseline in European Organization for Research and Treatment (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Combined Global Health Status / Quality of Life (Items 29 & 30) Scale Combined Score-2.43 (-8.69 to 3.83)-2.18 (-8.34 to 3.98)
Statistical analysis
  • Pembrolizumab + Lenvatinib vs Pembrolizumab + Placebo · cLDA model · p = 0.9519 · Difference in least square (ls) means: -0.25 · 95% CI -8.59 to 8.09Two-sided p-value based on cLDA model with covariates for treatment by study visit interaction; stratified by ECOG and baseline PDL-1.
SecondaryChange From Baseline in Cough (EORTC Quality of Life Questionnaire-Lung Cancer Module 13 [QLQ-LC13] Item 31) Score

The EORTC QLQ-LC13 is a lung cancer-specific supplemental questionnaire used in combination with the EORTC QLQ-C30. Participant responses to the question "How much did you cough?" are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. The change from baseline in cough (EORTC QLQ-LC13 Item 31) score will be presented. A lower score indicates a better outcome.

Time frame:
Baseline and Week 21
Reported as:
Least squares mean · Score on a scale
Change From Baseline in Cough (EORTC Quality of Life Questionnaire-Lung Cancer Module 13 [QLQ-LC13] Item 31) Score
Score on a scalePembrolizumab + LenvatinibPembrolizumab + Placebo
Change From Baseline in Cough (EORTC Quality of Life Questionnaire-Lung Cancer Module 13 [QLQ-LC13] Item 31) Score-2.97 (-9.97 to 4.04)-11.78 (-18.64 to -4.92)
Statistical analysis
  • Pembrolizumab + Lenvatinib vs Pembrolizumab + Placebo · cLDA model · p = 0.0628 · Difference in ls means: 8.81 · 95% CI -0.49 to 18.11Two-sided p-value based on cLDA model with covariates for treatment by study visit interaction; stratified by ECOG and baseline PDL-1.
SecondaryChange From Baseline in Chest Pain (EORTC QLQ-LC13 Item 40) Score

The EORTC QLQ-LC13 is a lung cancer-specific supplemental questionnaire used in combination with the EORTC QLQ-C30. Participant responses to the question "Have you had pain in your chest?" are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. The change from baseline in chest pain (EORTC QLQ-LC13 Item 40) score was reported. A lower score indicated a better outcome.

Time frame:
Baseline and Week 21
Reported as:
Least squares mean · Score on a scale
Change From Baseline in Chest Pain (EORTC QLQ-LC13 Item 40) Score
Score on a scalePembrolizumab + LenvatinibPembrolizumab + Placebo
Change From Baseline in Chest Pain (EORTC QLQ-LC13 Item 40) Score-3.84 (-9.95 to 2.28)-7.42 (-13.41 to -1.44)
Statistical analysis
  • Pembrolizumab + Lenvatinib vs Pembrolizumab + Placebo · cLDA model · p = 0.3298 · Difference in ls means: 3.59 · 95% CI -3.70 to 10.87Two-sided p-value based on cLDA model with covariates for treatment by study visit interaction; stratified by ECOG and baseline PDL-1.
SecondaryChange From Baseline in Dyspnea (EORTC QLQ-C30 Item 8) Score

The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant responses to the question "Were you short of breath?" are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. The change from baseline in dyspnea (EORTC QLQ-C30 Item 8) score was reported. A lower score indicated a better outcome.

Time frame:
Baseline and Week 21
Reported as:
Least squares mean · Score on a scale
Change From Baseline in Dyspnea (EORTC QLQ-C30 Item 8) Score
Score on a scalePembrolizumab + LenvatinibPembrolizumab + Placebo
Change From Baseline in Dyspnea (EORTC QLQ-C30 Item 8) Score0.54 (-7.85 to 8.94)0.82 (-7.41 to 9.06)
Statistical analysis
  • Pembrolizumab + Lenvatinib vs Pembrolizumab + Placebo · cLDA model · p = 0.9594 · Difference in ls means: -0.28 · 95% CI -11.32 to 10.75Two-sided p-value based on cLDA model with covariates for treatment by study visit interaction; stratified by ECOG and baseline PDL-1.
SecondaryChange From Baseline in Physical Functioning (EORTC QLQ-C30 Items 1-5) Score

EORTC QLQ-C30 is a questionnaire to assess the overall QoL of cancer patients. Participant responses to 5 questions about their physical functioning (Items 1 to 5) are scored on a 4-point scale (1=Not at All to 4=Very Much). The combined score of items 1 to 5 was computed by averaging the raw scores of the 5 items and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome. Per protocol, the change from baseline in EORTC QLQ-C30 physical functioning (Items 1-5) combined score was presented.

Time frame:
Baseline and Week 21
Reported as:
Least squares mean · Score on a scale
Change From Baseline in Physical Functioning (EORTC QLQ-C30 Items 1-5) Score
Score on a scalePembrolizumab + LenvatinibPembrolizumab + Placebo
Change From Baseline in Physical Functioning (EORTC QLQ-C30 Items 1-5) Score-5.15 (-10.78 to 0.48)0.38 (-5.08 to 5.84)
Statistical analysis
  • Pembrolizumab + Lenvatinib vs Pembrolizumab + Placebo · cLDA model · p = 0.1620 · Difference in ls means: -5.53 · 95% CI -13.37 to 2.31Two-sided p-value based on cLDA model with covariates for treatment by study visit interaction; stratified by ECOG and baseline PDL-1.
SecondaryTime to True Deterioration (TTD) in EORTC QLQ-C30 Combined Global Health Status /Quality of Life (Items 29 & 30) Scale Combined Score

EORTC QLQ-C30 is a questionnaire to assess QoL of cancer patients. Participant responses to questions on GHS ("How would you rate your overall health during the past week?") and QoL ("How would you rate your overall QoL during the past week?") were scored on a 7-point scale (1= Very poor to 7=Excellent). The combined score of GHS (Item 29) and QoL (Item 30) was computed by averaging raw scores of the 2 items and applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome. TTD was defined as the time from baseline to first onset of ≥10-point negative change (decrease) from baseline in GHS-QoL combined score. A longer TTD indicates a better outcome.

Time frame:
Up to approximately 25 months
Reported as:
Median · Months
Time to True Deterioration (TTD) in EORTC QLQ-C30 Combined Global Health Status /Quality of Life (Items 29 & 30) Scale Combined Score
MonthsPembrolizumab + LenvatinibPembrolizumab + Placebo
Time to True Deterioration (TTD) in EORTC QLQ-C30 Combined Global Health Status /Quality of Life (Items 29 & 30) Scale Combined ScoreNA (5.7 to NA)NA (8.9 to NA)
Statistical analysis
  • Pembrolizumab + Lenvatinib vs Pembrolizumab + Placebo · Stratified Log Rank · p = 0.9419 · Hazard ratio (hr): 1.03 · 95% CI 0.47 to 2.26Two-sided p-value based on log-rank test stratified by ECOG performance status and baseline PD-L1 status.
SecondaryTime to True Deterioration (TTD) in EORTC QLQ-LC13 Cough (Item 31) Scale Score

EORTC QLQ-LC13 is a lung cancer specific questionnaire. Participant responses to the question: "How much did you cough?" are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0-100. A lower score indicates a better outcome. TTD was defined as the time from baseline to first onset of ≥10-point negative change (decrease) from baseline in cough (Item 31). A longer TTD indicates a better outcome.

Time frame:
Up to approximately 25 months
Reported as:
Median · Months
Time to True Deterioration (TTD) in EORTC QLQ-LC13 Cough (Item 31) Scale Score
MonthsPembrolizumab + LenvatinibPembrolizumab + Placebo
Time to True Deterioration (TTD) in EORTC QLQ-LC13 Cough (Item 31) Scale ScoreNA (NA to NA)NA (NA to NA)
Statistical analysis
  • Pembrolizumab + Lenvatinib vs Pembrolizumab + Placebo · Stratified Log Rank · p = 0.9789 · Hazard ratio (hr): 1.01 · 95% CI 0.43 to 2.38Two-sided p-value based on log-rank test stratified by ECOG performance status and baseline PD-L1 status.
SecondaryTime to True Deterioration (TTD) in EORTC QLQ-LC13 Chest Pain (Item 40) Scale Score

EORTC QLQ-LC13 is a lung cancer specific questionnaire. Participant responses to the question: "Have you had pain in your chest?" are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0-100. A lower score indicates a better outcome. TTD was defined as the time from baseline to first onset of ≥10-point negative change (decrease) from baseline in cough (Item 40). A longer TTD indicates a better outcome.

Time frame:
Up to approximately 25 months
Reported as:
Median · Months
Time to True Deterioration (TTD) in EORTC QLQ-LC13 Chest Pain (Item 40) Scale Score
MonthsPembrolizumab + LenvatinibPembrolizumab + Placebo
Time to True Deterioration (TTD) in EORTC QLQ-LC13 Chest Pain (Item 40) Scale ScoreNA (NA to NA)NA (NA to NA)
Statistical analysis
  • Pembrolizumab + Lenvatinib vs Pembrolizumab + Placebo · Stratified Log Rank · p = 0.8856 · Hazard ratio (hr): 1.08 · 95% CI 0.36 to 3.28Two-sided p-value based on log-rank test stratified by ECOG performance status and baseline PD-L1 status.
SecondaryTime to True Deterioration (TTD) in EORTC QLQ-C30 Dyspnea (Item 8) Scale Score

EORTC QLQ-C30 is a questionnaire to assess the overall QoL of cancer patients. Participant responses to the question: "Were you short of breath?" are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A lower score indicates a better outcome. TTD was defined as the time from baseline to first onset of ≥10-point negative change (decrease) from baseline in dyspnea (Item 8). A longer TTD indicates a better outcome.

Time frame:
Up to approximately 25 months
Reported as:
Median · Months
Time to True Deterioration (TTD) in EORTC QLQ-C30 Dyspnea (Item 8) Scale Score
MonthsPembrolizumab + LenvatinibPembrolizumab + Placebo
Time to True Deterioration (TTD) in EORTC QLQ-C30 Dyspnea (Item 8) Scale ScoreNA (5.8 to NA)NA (8.9 to NA)
Statistical analysis
  • Pembrolizumab + Lenvatinib vs Pembrolizumab + Placebo · Stratified Log Rank · p = 0.3264 · Hazard ratio (hr): 1.55 · 95% CI 0.64 to 3.75Two-sided p-value based on log-rank test stratified by ECOG performance status and baseline PD-L1 status.
SecondaryTime to True Deterioration (TTD) in the Composite Endpoint of EORTC QLQ-LC13 Cough (Item 31), EORTC QLQ-LC13 Chest Pain (Item 40), or EORTC QLQ-C30 Dyspnea (Item 8)

The EORTC QLQ-C30 is a 30-item questionnaire developed to assess the QoL of cancer patients, including a single-item scale score for dyspnea (Item 8; score range:1=Not at All to 4=Very Much). Used in combination with QLQ-C30, the EORTC QLQ-LC13 is a supplemental lung cancer-specific module, including a single-item scale score for cough (Item 31; score range:1=Not at All to 4=Very Much ) and chest pain (Item 40, score range: 1=Not at All to 4=Very Much). The combined score of items 31, 40 and 8 was computed by averaging the raw scores of the items and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome. The TTD in the composite endpoint of EORTC QLQ-LC13 Item 31, EORTC QLQ-LC13 Item 40, EORTC QLQ-C30 Item 8 scale score was presented, defined as the time to first onset of a ≥10point decrease from baseline in anyone of the three scale items. A longer TTD indicates better outcome.

Time frame:
Up to approximately 25 months
Reported as:
Median · Months
Time to True Deterioration (TTD) in the Composite Endpoint of EORTC QLQ-LC13 Cough (Item 31), EORTC QLQ-LC13 Chest Pain (Item 40), or EORTC QLQ-C30 Dyspnea (Item 8)
MonthsPembrolizumab + LenvatinibPembrolizumab + Placebo
Time to True Deterioration (TTD) in the Composite Endpoint of EORTC QLQ-LC13 Cough (Item 31), EORTC QLQ-LC13 Chest Pain (Item 40), or EORTC QLQ-C30 Dyspnea (Item 8)5.78 (2.79 to NA)NA (3.45 to NA)
Statistical analysis
  • Pembrolizumab + Lenvatinib vs Pembrolizumab + Placebo · Stratified Log Rank · p = 0.4068 · Hazard ratio (hr): 1.31 · 95% CI 0.70 to 2.46Two-sided p-value based on log-rank test stratified by ECOG performance status and baseline PD-L1 status.
SecondaryTime to True Deterioration (TTD) Based on Change From Baseline in EORTC QLQ-C30 Physical Functioning (Items 1-5) Score

EORTC QLQ-C30 is a questionnaire to assess the overall QoL of cancer patients. Participant responses to 5 questions about their physical functioning (Items 1 to 5) are scored on a 4-point scale (1=Not at All to 4=Very Much). The combined score of items 1 to 5 was computed by averaging the raw scores of the 5 items and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome. TTD was defined as the time from baseline to first onset of ≥10-point negative change (decrease) from baseline in physical functioning (Items 1 to 5). A longer TTD indicates a better outcome.

Time frame:
Up to approximately 25 months
Reported as:
Median · Months
Time to True Deterioration (TTD) Based on Change From Baseline in EORTC QLQ-C30 Physical Functioning (Items 1-5) Score
MonthsPembrolizumab + LenvatinibPembrolizumab + Placebo
Time to True Deterioration (TTD) Based on Change From Baseline in EORTC QLQ-C30 Physical Functioning (Items 1-5) ScoreNA (6.2 to NA)NA (NA to NA)
Statistical analysis
  • Pembrolizumab + Lenvatinib vs Pembrolizumab + Placebo · Stratified Log Rank · p = 0.0020 · Hazard ratio (hr): 7.81 · 95% CI 1.71 to 35.62Two-sided p-value based on log-rank test stratified by ECOG performance status and baseline PD-L1 status.
PrimaryProgression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)

PFS was defined as the time from date of randomization to the date of the first documentation of progressive disease (PD) or death from any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. Note: The appearance of one or more new lesions was also considered PD. Data were from the product-limit (Kaplan-Meier) method for censored data. PFS as assessed by BICR per RECIST 1.1 was presented.

Time frame:
Up to approximately 18 months
Reported as:
Median · Months
Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)
MonthsPembrolizumab + LenvatinibPembrolizumab + Placebo
Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)6.1 (4.2 to 8.7)10.3 (5.6 to NA)
Statistical analysis
  • Pembrolizumab + Lenvatinib vs Pembrolizumab + Placebo · Stratified Log Rank · p = 0.71084 · Hazard ratio (hr): 1.18 · 95% CI 0.61 to 2.25One-sided p-value based on log-rank test stratified by ECOG performance status, geographic region of enrolling site and baseline PD-L1 status.
PrimaryOverall Survival (OS)

OS was defined as the time from date of randomization to date of death from any cause.

Time frame:
Up to approximately 18 months
Reported as:
Median · Months
Overall Survival (OS)
MonthsPembrolizumab + LenvatinibPembrolizumab + Placebo
Overall Survival (OS)11.4 (8.4 to NA)NA (NA to NA)
Statistical analysis
  • Pembrolizumab + Lenvatinib vs Pembrolizumab + Placebo · Stratified Log Rank · p = 0.81970 · Hazard ratio (hr): 1.53 · 95% CI 0.61 to 3.87One-sided p-value based on log-rank test stratified by ECOG performance status, geographic region of enrolling site and baseline PD-L1 status.

Adverse events

Collected over Up to approximately 52 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lenvatinib + Pembrolizumab28/49 (57.1%)24/49 (49%)49/49 (100%)
Placebo + Pembrolizumab32/58 (55.2%)17/58 (29.3%)54/58 (93.1%)
Most frequent serious events
Showing 10 of 39
Most frequent serious events
EventLenvatinib + PembrolizumabPlacebo + Pembrolizumab
PneumoniaInfections and infestations4/494/58
HaemoptysisRespiratory, thoracic and mediastinal disorders4/491/58
PneumonitisRespiratory, thoracic and mediastinal disorders3/490/58
DiarrhoeaGastrointestinal disorders2/490/58
PancreatitisGastrointestinal disorders2/491/58
Chest discomfortGeneral disorders2/490/58
DeathGeneral disorders2/491/58
Alanine aminotransferase increasedInvestigations2/490/58
Aspartate aminotransferase increasedInvestigations2/490/58
Decreased appetiteMetabolism and nutrition disorders2/490/58
Most frequent other events
Showing 10 of 72
Most frequent other events
EventLenvatinib + PembrolizumabPlacebo + Pembrolizumab
ProteinuriaRenal and urinary disorders26/4911/58
HypothyroidismEndocrine disorders22/4911/58
Weight decreasedInvestigations21/492/58
HypertensionVascular disorders21/497/58
DiarrhoeaGastrointestinal disorders20/498/58
Aspartate aminotransferase increasedInvestigations17/4916/58
AnaemiaBlood and lymphatic system disorders14/4916/58
Alanine aminotransferase increasedInvestigations14/4913/58
Decreased appetiteMetabolism and nutrition disorders14/498/58
Platelet count decreasedInvestigations13/494/58

Baseline characteristics

All Chinese participants who were randomized to the global study (NCT03829332) or to the extension portion.

Age, Continuous
Age, Continuous(Years)Pembrolizumab + LenvatinibPembrolizumab + PlaceboTotal
Mean64.2 ± 8.264.2 ± 7.664.2 ± 7.8
Sex: Female, Male
Sex: Female, Male(Participants)Pembrolizumab + LenvatinibPembrolizumab + PlaceboTotal
Female71017
Male424890
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Pembrolizumab + LenvatinibPembrolizumab + PlaceboTotal
Hispanic or Latino000
Not Hispanic or Latino4958107
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Pembrolizumab + LenvatinibPembrolizumab + PlaceboTotal
American Indian or Alaska Native000
Asian4958107
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
Eastern Cooperative Oncology Group (ECOG) Performance Status
Eastern Cooperative Oncology Group (ECOG) Performance Status(Participants)Pembrolizumab + LenvatinibPembrolizumab + PlaceboTotal
ECOG=061016
ECOG=1434891
Programmed Cell Death Ligand 1 (PD-L1) Status at Baseline
Programmed Cell Death Ligand 1 (PD-L1) Status at Baseline(Participants)Pembrolizumab + LenvatinibPembrolizumab + PlaceboTotal
TPS=1-49%213354
TPS≥ 50%282553
Geographic Region
Geographic Region(Participants)Pembrolizumab + LenvatinibPembrolizumab + PlaceboTotal
East Asia4958107
Non-East Asia000
08

Study locations

17 sites
  • Anhui Provincial Hospital ( Site 0108)
    Hefei, Anhui 230001, China
  • The First Affiliated Hospital of Anhui Medical University ( Site 0113)
    Hefei, Anhui 230088, China
  • Peking Union Medical College Hospital ( Site 0105)
    Beijing, Beijing 100006, China
  • Beijing Cancer Hospital ( Site 0102)
    Beijing, Beijing 100036, China
  • Beijing Chest Hospital Capital Medical University ( Site 0111)
    Beijing, Beijing 101149, China
  • Xiangya Hospital of Central South University ( Site 0115)
    Changsha, Hunan 410008, China
  • Hunan Cancer Hospital ( Site 0104)
    Changsha, Hunan 410013, China
  • Zhongshan Hospital Fudan University ( Site 0100)
    Shanghai, Hunan 200032, China
  • Jiangsu Cancer Hospital ( Site 0101)
    Nanjing, Jiangsu 210009, China
  • The First Hospital of Jilin University ( Site 0110)
    Chang chun, Jilin 130021, China
  • Shanghai Chest Hospital ( Site 0112)
    Shanghai, Shanghai 200030, China
  • 1st Affil Hosp of Med College of Xi'an Jiaotong University ( Site 0103)
    XiAn, Shanxi 710061, China
  • West China Hospital of Sichuan University ( Site 0117)
    Chengdu, Sichuan 18215516050, China
  • The First Affiliated Hospital Zhejiang University ( Site 0106)
    Hangzhou, Zhejiang 310003, China
  • Hangzhou First People's Hospital ( Site 0109)
    Hangzhou, Zhejiang 310006, China
  • 2nd Affil Hosp of Zhejiang University College of Medicine ( Site 0114)
    Hangzhou, Zhejiang 310009, China
  • Zhejiang Cancer Hospital ( Site 0116)
    Hangzhou, Zhejiang 310022, China
09

References and documents

Publications

  • Yang JC, Han B, De La Mora Jimenez E, Lee JS, Koralewski P, Karadurmus N, Sugawara S, Livi L, Basappa NS, Quantin X, Dudnik J, Ortiz DM, Mekhail T, Okpara CE, Dutcus C, Zimmer Z, Samkari A, Bhagwati N, Csoszi T. Pembrolizumab With or Without Lenvatinib for First-Line Metastatic NSCLC With Programmed Cell Death-Ligand 1 Tumor Proportion Score of at least 1% (LEAP-007): A Randomized, Double-Blind, Phase 3 Trial. J Thorac Oncol. 2024 Jun;19(6):941-953. doi: 10.1016/j.jtho.2023.12.023. Epub 2023 Dec 29. PubMed 38159809 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2019 to primary completion in May 2021, 18 months.

Results were first posted in Nov 2022, 1 year 5 months after primary completion. A results delay was requested in Mar 2022.

Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's 18 months is below that.

Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2020
First posted
Dec 21, 2020
StartActual
Oct 23, 2019
Primary completionActual
May 19, 2021
CompletionActual
Mar 29, 2024
Results delay requested
Mar 17, 2022
Results first posted
Nov 9, 2022
Last update
Apr 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04676412
Collaborators
Eisai Inc.
Responsible party
Sponsor
First posted
Dec 21, 2020
Start date
Oct 23, 2019
Primary completion
May 19, 2021
Completion
Mar 29, 2024
Results posted
Nov 9, 2022
Last update
Apr 4, 2025

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lenvatinib

Start the discussion